Literature DB >> 22595828

Prognostic value of risk score and urinary markers in idiopathic membranous nephropathy.

Jan A J G van den Brand1, Julia M Hofstra, Jack F M Wetzels.   

Abstract

BACKGROUND AND OBJECTIVES: Accurate prediction of prognosis may improve management of patients with idiopathic membranous nephropathy. This study compared the Toronto Risk Score and urinary low-molecular weight proteins. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: One hundred four patients with biopsy-proven idiopathic membranous nephropathy who presented between 1995 and 2008 with a well-preserved kidney function and nephrotic range proteinuria were included. Urinary β2-microglobulin and α1-microglobulin measurements were obtained by timed standardized measurements, and the Toronto Risk Score was calculated using data obtained from medical records. The endpoint was progression, which was defined as an increase in serum creatinine > 50% or > 25% with a concentration > 135 μmol/L.
RESULTS: Forty-nine patients showed progression. The area under the receiver-operating characteristics curve was 0.78 (95% confidence interval = 0.69-0.88) for the risk score versus 0.80 (0.71-0.89) and 0.79 (0.71-0.88) for urinary β2- and α1-microglobulin, respectively. Differences were not significant. Persistent proteinuria did not add accuracy to the Toronto Risk Score. Conversely, its accuracy was not reduced when data from the first 6 months of follow-up were used. Furthermore, a score based on GFR estimated with the six-variable Modification of Diet in Renal Disease equation, calculated in the first 6 months of follow-up, gave an area under the receiver-operating characteristics curve of 0.83 (0.74-0.92), which was not statistically different from other markers.
CONCLUSIONS: The prognostic accuracies of the Toronto Risk Score and urinary low-molecular weight proteins were not significantly different. The risk score can be calculated within 6 months of diagnosis, and a simplified risk score using estimated GFR-Modification of Diet in Renal Disease may be sufficient.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595828      PMCID: PMC3408119          DOI: 10.2215/CJN.00670112

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  21 in total

1.  Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis.

Authors:  Claudio Bazzi; Concetta Petrini; Virginia Rizza; Girolamo Arrigo; Pietro Napodano; Maria Paparella; Giuseppe D'Amico
Journal:  Nephrol Dial Transplant       Date:  2002-11       Impact factor: 5.992

2.  Atrial natriuretic peptide increases albuminuria in type I diabetic patients: evidence for blockade of tubular protein reabsorption.

Authors:  E M Jacobs; G Vervoort; A J Branten; I Klasen; P Smits; J F Wetzels
Journal:  Eur J Clin Invest       Date:  1999-02       Impact factor: 4.686

3.  Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.

Authors:  D C Cattran; Y Pei; C M Greenwood; C Ponticelli; P Passerini; E Honkanen
Journal:  Kidney Int       Date:  1997-03       Impact factor: 10.612

4.  Urinary transforming growth factor-beta 1 in membranous glomerulonephritis.

Authors:  E Honkanen; A M Teppo; T Törnroth; P H Groop; C Grönhagen-Riska
Journal:  Nephrol Dial Transplant       Date:  1997-12       Impact factor: 5.992

5.  Urinary excretion of beta2-microglobulin and IgG predict prognosis in idiopathic membranous nephropathy: a validation study.

Authors:  Amanda J W Branten; Peggy W du Buf-Vereijken; Ina S Klasen; Frank H Bosch; Geert W Feith; Daan A Hollander; Jack F Wetzels
Journal:  J Am Soc Nephrol       Date:  2004-11-24       Impact factor: 10.121

6.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

Review 7.  Prognostic factors in idiopathic membranous nephropathy.

Authors:  L J Reichert; R A Koene; J F Wetzels
Journal:  Am J Kidney Dis       Date:  1998-01       Impact factor: 8.860

8.  Urinary excretion of cytokines and complement SC5b-9 in idiopathic membranous glomerulonephritis.

Authors:  E Honkanen; A M Teppo; S Meri; T Lehto; C Grönhagen-Riska
Journal:  Nephrol Dial Transplant       Date:  1994       Impact factor: 5.992

9.  Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy.

Authors:  S P Kon; B Coupes; C D Short; L R Solomon; M J Raftery; N P Mallick; P E Brenchley
Journal:  Kidney Int       Date:  1995-12       Impact factor: 10.612

10.  Predicting chronic renal insufficiency in idiopathic membranous glomerulonephritis.

Authors:  Y Pei; D Cattran; C Greenwood
Journal:  Kidney Int       Date:  1992-10       Impact factor: 10.612

View more
  21 in total

1.  Urinary Volatile Organic Compounds as Potential Biomarkers in Idiopathic Membranous Nephropathy.

Authors:  Mingao Wang; Rujuan Xie; Xibei Jia; Ruichan Liu
Journal:  Med Princ Pract       Date:  2017-06-19       Impact factor: 1.927

2.  Glomerular disease: Predicting outcomes in idiopathic membranous nephropathy.

Authors:  Manuel Praga; Jorge Rojas-Rivera
Journal:  Nat Rev Nephrol       Date:  2012-07-17       Impact factor: 28.314

Review 3.  Novel biomarkers in glomerular disease.

Authors:  Yasar Caliskan; Krzysztof Kiryluk
Journal:  Adv Chronic Kidney Dis       Date:  2014-03       Impact factor: 3.620

4.  Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.

Authors:  Elion Hoxha; Ina Thiele; Gunther Zahner; Ulf Panzer; Sigrid Harendza; Rolf A K Stahl
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

Review 5.  Treatment of primary membranous nephropathy: where are we now?

Authors:  Andrea Angioi; Nicola Lepori; Ana Coloma López; Sanjeev Sethi; Fernando C Fervenza; Antonello Pani
Journal:  J Nephrol       Date:  2017-09-05       Impact factor: 3.902

Review 6.  Treatment of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Fernando C Fervenza; Jack F M Wetzels
Journal:  Nat Rev Nephrol       Date:  2013-07-02       Impact factor: 28.314

Review 7.  Primary membranous nephropathy: an endless story.

Authors:  Ponticelli Claudio
Journal:  J Nephrol       Date:  2022-10-17       Impact factor: 4.393

8.  HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy.

Authors:  Gemma Bullich; José Ballarín; Artur Oliver; Nadia Ayasreh; Irene Silva; Sheila Santín; Montserrat M Díaz-Encarnación; Roser Torra; Elisabet Ars
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

9.  Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study.

Authors:  Anne-Els van de Logt; Charles H Beerenhout; Hans S Brink; Jos J van de Kerkhof; Jack F Wetzels; Julia M Hofstra
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

10.  TRPC6 single nucleotide polymorphisms and progression of idiopathic membranous nephropathy.

Authors:  Julia M Hofstra; Marieke J H Coenen; Mascha M V A P Schijvenaars; Jo H M Berden; Johan van der Vlag; Lies H Hoefsloot; Nine V A M Knoers; Jack F M Wetzels; Tom Nijenhuis
Journal:  PLoS One       Date:  2014-07-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.